Thomas Jefferson University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Thomas Jefferson University sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
Thomas Jefferson University: 292 sponsored US clinical trials, 54 recruiting.
Thomas Jefferson University sponsors 292 registered US clinical trials on ClinicalTrials.gov, 54 of them currently recruiting, and 182 completed. 46 of these trials are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Solid Neoplasm, with 4 trials.
Top-decile sponsor footprint
Thomas Jefferson University ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
182 of 210 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 1 of 6
Radiotherapy for Refractory Hidradenitis Suppurativa
NCT07414550
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
NCT07417488
Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
NCT07436364
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
NCT07501650
Intra-aortic Balloon Counterpulsation (IABC) Compliance
NCT07402018
ACT With CF Self-Help Toolkit
NCT07436351
Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry
NCT07574645
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
NCT07234968
From Screening to Support: A Multi-Method Analysis of HRSN Integration in Cancer Care
NCT07352579
Preoperative Opioid Tapering Before Spine Surgery
NCT07221786
PopSci CHW4CervixHealth
NCT07336134
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
NCT07188090
Tebentafusp-tebn With LDT in Metastatic UM
NCT06626516
Surviving Daily Life
NCT07054723
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
NCT07184775
Non-Invasive Interventions for Respiratory Recovery in Chronic Spinal Cord Injury
NCT07135583
Y-90 Treatment Response Using Transarterial Radioembolization
NCT07145801
Neoadjuvant Tebentafusp for Uveal Melanoma
NCT06414590
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
NCT07102641
Excretion of Rivaroxaban in Human Breast Milk
NCT06831474
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
NCT06826859
Home Blood Transfusions
NCT07121140
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
NCT06789159
Advanced Neuroimaging in Idiopathic Intracranial Hypertension
NCT06950099
Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE
NCT06705075
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
NCT05487846
Targeted EHR-based Communication of Diagnostic Uncertainty in the ED
NCT06638021
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
NCT06419803
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
NCT06419777
Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes
NCT06632587
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
NCT05627219
LATe Cerclage in High-risk Pregnancies (LATCH)
NCT06036446
Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
NCT06918223
Can Medical Cannabis Affect Opioid Use?
NCT06206252
Tazemetostat and Palbociclib With CPX-351for R/R AML
NCT05627232
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
NCT05929664
TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
NCT05804240
Telehealth Intervention for Autism Spectrum Disorder
NCT04832152
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
NCT05775939
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT07478016
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
NCT05470205
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
NCT05502523
Neoadjuvant Breast Cancer Time Restricted Eating
NCT05327608
Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality
NCT05031910
SHAPE of Portal Hypertension in Children
NCT04720456
Two Step Haplo With Radiation Conditioning
NCT05031897
Early Antenatal Support for Iron Deficiency Anemia
NCT04278651
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT04959474
Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
NCT04602767
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
NCT04788277
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 34 |
| Phase 3 | 19 |
| Phase 4 | 27 |
What is open in the Thomas Jefferson University pipeline
54 recruiting of 292 indexed (18% open); 182 completed (62%).
Phase mix: 46 late (III/IV) vs 73 early (I/II) (early-phase heavy).
Top condition: Malignant Solid Neoplasm (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Thomas Jefferson University: open-pipeline peers nationwide
Peers matched on 292 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Thomas Jefferson University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- University of Michigan Rogel Cancer Center · 292 trials · 15% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Florida Atlantic University · 19% recruiting · 27 trials
- Institut de Recherches Internationales Servier · 19% recruiting · 27 trials
- Natera · 19% recruiting · 27 trials
- Nemours Children's Clinic · 19% recruiting · 108 trials
Related
What to do with this Thomas Jefferson University page
292 registered trials is a research-attention snapshot, not an endorsement of Thomas Jefferson University or any single study.
- 54 of Thomas Jefferson University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malignant Solid Neoplasm is the condition Thomas Jefferson University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Thomas Jefferson University pipeline card: 292 registered trials from official public datasets.Report a data error.